| 徐永祥,李祥勇,孙凯.两种放射治疗计划系统的对比验证研究[J].中华放射医学与防护杂志,2011,31(4):465-467.XU Yong-xiang,LI Xiang-yong,SUN Kai.Clinical verification of Neptune 3D-RTPS-A treatment planning system compared to Prowess TPS[J].Chin J Radiol Med Prot,2011,31(4):465-467 |
| 两种放射治疗计划系统的对比验证研究 |
| Clinical verification of Neptune 3D-RTPS-A treatment planning system compared to Prowess TPS |
| 投稿时间：2011-01-04 |
| DOI：10.3760/cma.j.issn.0254-5098.2011.04.023 |
| 中文关键词: 治疗计划系统 临床验证 准确性 安全性 |
| 英文关键词:Treatment planning system(TPS) Clinical verification Validity Safety |
| 基金项目: |
|
| 摘要点击次数: 4116 |
| 全文下载次数: 3581 |
| 中文摘要: |
| 目的 对比Prowess 治疗计划系统(TPS)以检验 Neptune 3D-RTPS-A放射治疗计划系统在临床应用过程中的准确性和安全性。方法 选取2009年9月至2010年5月在Prowess TPS行三维放疗计划设计并顺利完成适形放疗的30例肿瘤病例,将Prowess TPS中勾画的外轮廓、危及器官、靶区导入到Neptune TPS,并在Neptune TPS中设置和Prowess TPS相同的治疗计划参数,对比2种TPS计算的结果数据。结果 使用Neptune 3D-RTPS-A三维治疗计划系统能够顺利完成所选30例肿瘤病例的放射治疗计划设计。与Prowess TPS比较,源皮距SSD差异<0.5%;机器跳数(MU)差异<0.5%;等中心剂量差异<2%;30%、50%、70%、80%、90% 5条等剂量线包绕面积差异<3%,等中心平面上的等剂量线位置平均偏差0.43 mm;30例患者PTV的 V 90差异<2%,危及器官 V 30差异<3%。结论 Neptune 3D-RTPS-A三维治疗计划系统具备临床应用的准确性和安全性。 |
| 英文摘要: |
| Objective To investigate the safety and validity of Neptune 3D-RTPS-A treatment planning system compared to Prowess TPS. Methods A total of 30 clinical tumor cases with radiotherapy planning on Prowess TPS from September 2009 to May 2010 were used. The contours, organs at risk and target volumes in Prowess TPS were transported into Neptune TPS, the same parameters setted in the two treatment planning systems. The results of comparison of the two TPS were calculated. Results All cases of clinical treatment planning were completed successfully by Neptune TPS, and the various functions of the design were achieved for fitting tumor conformal radiation therapy.The key parameters on radiation treatment were compared.The results are as follows: the differences of source skin distance (SSD) <0.5%, differences of Monitor Unites <0.5%, the differences of dose at isocenter <2%, the differences of five isodose lines surrounding area <3%, and the mean difference of distances of five isodose lines was 0.43 mm, the differences of the volume of PTV on 90% isodose line<2%, and the differences in V30 of organs at risk<3%. Conclusions Neptune TPS could be qualified for clinical validity and safety by clinical verification. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|